(Q40465101)

20 September 2017

title

Cefepime monotherapy for treatment of febrile neutropenia in children. (English)

1 reference

20 September 2017

Hany Ariffin

1

1 reference

20 September 2017

Chong Lee Ai

series ordinal

2

1 reference

20 September 2017

Chan Lee Lee

series ordinal

3

1 reference

20 September 2017

Wan Ariffin Abdullah

series ordinal

4

1 reference

20 September 2017

publication date

1 December 2006

1 reference

Journal of Paediatrics and Child Health

20 September 2017

published in

1 reference

20 September 2017

volume

42

1 reference

20 September 2017

issue

12

1 reference

20 September 2017

page(s)

781-784

1 reference

Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Antibiotic resistance patterns in nosocomial gram-negative bacterial infections in units with heavy antibiotic usage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1754.2006.00977.X

10.1111/J.1440-1754.2006.00977.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference